Literature DB >> 24126121

Time for more optimism in metastatic breast cancer?

Elżbieta Senkus1, Fatima Cardoso, Olivia Pagani.   

Abstract

Treatment of metastatic breast cancer has substantially changed in the last decades. Availability of new cytotoxics and targeted therapies as well as changes in treatment philosophy and strategy have all contributed to a significant improvement in both survival and patients' quality of life. The multidisciplinary approach, personalised treatments based on tumour characteristics, patient's and disease history, as well as re-definition of treatment goals, aiming at the lowest possible impact on patients' life by replacing aggressive multidrug chemotherapy with single-agent cytotoxic treatment or endocrine±targeted therapies, have all been the bases of the new treatment paradigm. More recently the development of the international advanced breast cancer (ABC) consensus guidelines have further contributed to this improvement. This review will focus on the major achievements and challenges in the different tumour subtypes and sites, with a focus on future research topics and trends.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ABC guidelines; Chemotherapy; Endocrine therapy; Intrinsic subtypes; Metastatic breast cancer; Targeted therapy

Mesh:

Substances:

Year:  2013        PMID: 24126121     DOI: 10.1016/j.ctrv.2013.09.015

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  22 in total

1.  Implication of duration of clinical presentation on tumor progression and short-term recurrence in patients with early breast cancer.

Authors:  Takaaki Fujii; Reina Yajima; Hiroki Morita; Toshinaga Suto; Hironori Tatsuki; Soichi Tsutsumi; Hiroyuki Kuwano
Journal:  Mol Clin Oncol       Date:  2015-04-03

2.  Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.

Authors:  Dinesh Vyas; Nicolas Lopez-Hisijos; Sulakshana Gandhi; M El-Dakdouki; Marc D Basson; Mary F Walsh; X Huang; Arpita K Vyas; Lakshmi S Chaturvedi
Journal:  J Nanosci Nanotechnol       Date:  2015-09

3.  Virtual High-Throughput Screening To Identify Novel Activin Antagonists.

Authors:  Jie Zhu; Rama K Mishra; Gary E Schiltz; Yogeshwar Makanji; Karl A Scheidt; Andrew P Mazar; Teresa K Woodruff
Journal:  J Med Chem       Date:  2015-07-07       Impact factor: 7.446

4.  Trastuzumab Targeted Neratinib Loaded Poly-Amidoamine Dendrimer Nanocapsules for Breast Cancer Therapy.

Authors:  Fadilah Sfouq Aleanizy; Fulwah Yahya Alqahtani; Sara Seto; Nora Al Khalil; Lama Aleshaiwi; Manar Alghamdi; Bushra Alquadeib; Hamad Alkahtani; Amal Aldarwesh; Qamraa Hamad Alqahtani; Hosam Gharib Abdelhady; Ibrahim Alsarra
Journal:  Int J Nanomedicine       Date:  2020-07-30

Review 5.  Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?

Authors:  Simona Di Lascio; Olivia Pagani
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

6.  Discovery of New Acid Ceramidase-Targeted Acyclic 5-Alkynyl and 5-Heteroaryl Uracil Nucleosides.

Authors:  Andrijana Meščić; Anja Harej; Marko Klobučar; Danijel Glavač; Mario Cetina; Sandra Kraljević Pavelić; Silvana Raić-Malić
Journal:  ACS Med Chem Lett       Date:  2015-10-05       Impact factor: 4.345

7.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

Authors:  Rita Nanda; Laura Q M Chow; E Claire Dees; Raanan Berger; Shilpa Gupta; Ravit Geva; Lajos Pusztai; Kumudu Pathiraja; Gursel Aktan; Jonathan D Cheng; Vassiliki Karantza; Laurence Buisseret
Journal:  J Clin Oncol       Date:  2016-05-02       Impact factor: 44.544

8.  Structural mass spectrometry of tissue extracts to distinguish cancerous and non-cancerous breast diseases.

Authors:  Kelly M Hines; Billy R Ballard; Dana R Marshall; John A McLean
Journal:  Mol Biosyst       Date:  2014-11

9.  Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients.

Authors:  Eran Sadot; Ser Yee Lee; Constantinos T Sofocleous; Stephen B Solomon; Mithat Gönen; T Peter Kingham; Peter J Allen; Ronald P DeMatteo; William R Jarnagin; Clifford A Hudis; Michael I D'Angelica
Journal:  Ann Surg       Date:  2016-07       Impact factor: 12.969

10.  RLIP inhibition suppresses breast-to-lung metastasis.

Authors:  Jyotsana Singhal; Shireen Chikara; David Horne; Ravi Salgia; Sanjay Awasthi; Sharad S Singhal
Journal:  Cancer Lett       Date:  2019-01-23       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.